TScan Therapeutics Announces FDA Clearance of Three Investigational New Drug Applications for the Treatment of Solid Tumors
WALTHAM, Mass., Jan. 23, 2023 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) applications for T-Plex, TSC-204-A0201, and TSC-204-C0702.
Surface Oncology Announces First Patient Dosed in a Phase 1/2 Study Evaluating SRF114, a Potential Best-In-Class Anti-CCR8 Antibody, in Patients with Advanced Solid Tumors
CAMBRIDGE, Mass., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that the first patient has been dosed in its Phase 1/2 clinical study investigating SRF114, a potential best-in-class, fully human, afucosylated anti-CCR8 antibody, as a monotherapy in patients with advanced solid tumors.
89bio Provides Business Update and Outlook for 2023
SAN FRANCISCO, Jan. 04, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today provided a corporate update, including its roadmap for advancing pegozafermin in 2023.
Boehringer Ingelheim and Click Therapeutics expand their existing Collaboration to develop Prescription Digital Therapeutics for Schizophrenia
Ingelheim, Germany and New York, New York, 19 December 2022 - Boehringer Ingelheim and Click Therapeutics today announced the launch of an expanded collaboration for the development and commercialization of a second prescription-based digital therapeutic (PDT). The companies will collaborate to develop and commercialize a novel mobile application, which combines multiple clinically validated therapeutic interventions for use alone and in combination with pharmaceutical therapy to help people with schizophrenia achieve positive clinical outcomes. The partnership aims to provide additional treatment options to those living with schizophrenia, where there remains a significant unmet need due to lack of access to psychosocial intervention therapies.
CEPI Boosts ‘Coronavirus X’ Vaccine Search with Expanded VBI Vaccines Deal
The Coalition for Epidemic Preparedness Innovations (CEPI) is expanding its world-leading portfolio of potential variant-proof coronavirus vaccines in a deal with VBI Vaccines Inc. (Nasdaq: VBIV) to advance the development of multivalent coronavirus shots that could be deployed against COVID-19 as well as a future ‘Coronavirus X’.
Ribon Therapeutics Announces Acquisition of Pre-Clinical CD38 Program by Boehringer Ingelheim
Cambridge, MA – November 29, 2022 – Ribon Therapeutics, a clinical stage biotechnology company developing therapeutics targeting stress support pathways, today announced that it entered into an agreement on the acquisition of its CD38 program with Boehringer Ingelheim. This includes a small molecule inhibitor designed to modulate intra- and extracellular CD38 activity, potentially restoring immune function in various diseases, as well as corresponding patents and other proprietary information. Boehringer Ingelheim aims to develop novel therapies based on Ribon’s CD38 program to transform the lives of patients with immunological and fibrotic diseases.
DispatchHealth Raises More Than $330 Million to Expand Its Technology-Enabled Ecosystem of High Acuity Care in the Home
DENVER, Nov. 23, 2022 /PRNewswire/ -- DispatchHealth, the nation’s first comprehensive in-home, high acuity medical care provider, today announced it has raised more than $330 million in combined equity and debt financing. The equity round of $259 million was led by Optum Ventures, with participation from new investors Adams Street Partners, Blue Shield of California, among others, and continued support from existing investors Humana, Echo Health Ventures, Questa Capital and Oak HC/FT. K2 HealthVentures, Silicon Valley Bank and SVB Capital provided debt financing of $75 million, with up to an additional $75 million available for growth initiatives, bringing the total raised to more than $400 million.
Surface Oncology Announces Promising SRF388 Monotherapy Data in Non-Small Cell Lung Cancer (NSCLC), Opening Second Stage of Monotherapy Trial and NSCLC Pembrolizumab Combination Cohort
CAMBRIDGE, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today provided a corporate update and reported financial results for the third quarter of 2022.
Inari Raises $124 Million to Design Seeds for a More Sustainable Food System
CAMBRIDGE, Mass., October 4, 2022 — Inari today announced that it secured $124 million in the successful completion of its latest fundraise. Working to deliver nature-positive solutions, the SEEDesign™ company’s cumulative equity raised now totals $475 million. The investment will further advance Inari’s leading position in multiplex gene-edited seed technology, support expansion of company product development and ultimately deliver new value in the commercial seed market.
VBI Vaccines Secures $100 Million Debt Facility From K2 HealthVentures
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced it has entered into a refinanced and upsized debt facility of up to $100 million with its existing lender, K2 HealthVentures (K2HV), a healthcare-focused specialty finance company.
TScan Therapeutics Secures Convertible Debt Facility for up to $60 Million with K2 HealthVentures
WALTHAM, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that it has entered into a debt financing facility for up to $60 million with K2 HealthVentures (K2HV), a healthcare-focused specialty finance company.
InterWell Health, Cricket Health, and Fresenius Health Partners Complete Three-Way Merger, Creating Premier, Value-based Kidney Care Provider
CAMBRIDGE, Mass., Aug. 24, 2022 /PRNewswire/ -- InterWell Health today announced it has completed a three-way merger between Fresenius Medical Care's value-based care division, Fresenius Health Partners; InterWell Health, a leading physician organization driving innovation in the kidney care industry; and Cricket Health, a provider of value-based kidney care with an industry-leading patient engagement and data platform. The new independent company, which will operate under the InterWell Health brand, will set the standard in value-based kidney care by partnering with a patient's nephrologist, improving their care delivery throughout the entire spectrum of their journey with kidney disease. With extraordinary capabilities, expertise, and reach, the new company expects to improve health outcomes for individuals with kidney disease and reduce costs to public and private payers, health systems, and all others that take risk for this vulnerable and complex patient population. The transaction has satisfied customary closing conditions and received regulatory clearance in the U.S.
Elevation Oncology Secures $50 Million Loan Facility with K2 HealthVentures
NEW YORK, July 28, 2022 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision oncology products for patients with genomically defined cancers, today announced that it has secured a $50 million senior secured loan facility from funds managed by K2 HealthVentures, a leading healthcare-focused investment firm. The initial proceeds from the facility will primarily support the exclusive license of EO-3021 (SYSA1801) outside of Greater China from CSPC Pharmaceutical Group and the execution of the Company's pipeline.
Inozyme Pharma Secures Flexible Debt Facility for up to $70 Million with K2 HealthVentures
BOSTON, July 26, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced that it has entered into a debt financing facility for up to $70 million with K2 HealthVentures (K2HV), a healthcare-focused specialty finance company.
Ribon Therapeutics Secures $50 Million in Growth Capital from K2 HealthVentures
Cambridge, MA – April 26, 2022 – Ribon Therapeutics, a clinical stage biotechnology company developing therapeutics targeting stress support pathways, today announced a $50 million debt financing facility from K2 HealthVentures (K2HV), a healthcare and life sciences-focused investment firm. Proceeds will be used to continue clinical and preclinical development of Ribon’s portfolio of selective, small molecule inhibitors to NAD+-utilizing enzymes.
Oncorus Announces Debt Capital Facility with K2 HealthVentures with $20 Million Funded at Closing, Relocation of Corporate Headquarters and Extension of Cash Runway
CAMBRIDGE, Mass., April 05, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announced that it has entered into a loan and security agreement with K2 HealthVentures (K2HV), a healthcare focused specialty finance company. Also today, Oncorus announced plans to relocate all its operations to its facility in Andover, Massachusetts in the fourth quarter of 2022, to allow research, process development and Good Manufacturing Practice (GMP)-compliant manufacturing to occur all in one facility. As a result of the term loan facility and operations relocation, as well as other initiatives to increase operational efficiency, Oncorus now expects its cash, cash equivalents and investments to fund its capital expenditures and operating expenses into early 2024.
Invaio Sciences Secures $50 Million Debt Financing to Develop and Commercialize Agricultural Solutions to Address Climate Change
CAMBRIDGE, Mass., Oct. 13, 2021 /PRNewswire/ -- Invaio Sciences, Inc., a Flagship Pioneering company unlocking the potential of natural systems to accelerate the transition to sustainable agriculture to urgently address climate change, has entered into a $50 million loan and security agreement with K2 HealthVentures (K2HV), a healthcare and life sciences-focused investment firm.
Aptinyx Secures $50 Million Growth Capital Credit Facility from K2 HealthVentures
EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that it has entered into a $50 million loan facility and security agreement with K2 HealthVentures (K2HV). The funds will provide general growth capital as Aptinyx advances its late-stage clinical pipeline of novel NMDA modulators.
ASLAN Pharmaceuticals Announces Loan Facility Providing Up to $45 Million From K2 HealthVentures
ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that it has closed a secured loan facility provided by K2 HealthVentures (K2HV). Under the terms of the facility, K2HV will provide ASLAN up to $45 million of secured debt financing. The facility consists of a $20 million initial term loan funded at closing, with the remaining $25 million subject to certain terms and conditions.
Vesta Healthcare Announces $65M in Growth Capital to Transform Care for High Needs Members and their Caregivers
Vesta Healthcare, a 24/7 clinical provider group and digital health platform, dedicated to supporting high needs members at home and connecting their caregivers’ insights to the rest of the care team, announced the raise of $65M in growth capital. The financing was led by Deerfield Management Company with participation from existing investors Oak HC/FT, Kaiser Permanente Ventures, Lux Capital, Generator Ventures, Nationwide, CareCentrix and Epstein Partners as well as new participation from K2 HealthVentures and an unnamed investor.